Aqilion recently announced positive results from the phase I study with their candidate AQ280. The candidate targets eosinophilic esophagitis and is tested in Aqilion’s Regulus programme. CEO Sarah Fredriksson visited BioStock’s studio to tell us more about the phase I results and the plans for a potential IPO.
See the interview with Aqilion’s CEO Sarah Fredriksson below.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.